Chinese guidelines (24) recommend pyrotinib (a HER2-targeted inhibitor) plus chemotherapy as a choice of salvage treatment regimens for HER2-positve breast cancer if prior treatment with trastuzumab has failed. The gene discussed is ERBB2; the disease is breast carcinoma.